 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Epizyme
EPZM
conference date: May 10, 2022 @ 5:30 AM Pacific Time
Epizyme Stock Soars 60% on Ipsen Acquisition [June 32, 2020 @ Seeking Alpha]
Epizyme Comeback Is Likely, Price Makes It A Buy by William Meyers [March 30, 2021 @ Seeking Alpha]
Epizyme A Buy For Tazverik And Epigenetic Platform [July 1, 2020 @ Seeking Alpha]
Epizyme A Buy On Firmer Tazemetostat Timeline by William Meyers [June 5, 2019 @ Seeking Alpha]
Epizyme As A Strategic Acquisition For Epigenetic Therapies by William Meyers [March 6, 2019 @ Seeking Alpha]
| 2022 | |||
| Epizyme Q1 2022 |
|||
| May 10, 2022 | |||
| 2021 | |||
| Epizyme Q1 2021 |
Epizyme Q2 2021 |
Epizyme Q3 2021 |
Epizyme Q4 2021 |
| May 6, 2021 | Aug. 9, 2021 | Nov. 9, 2021 | March 1, 2022 |
| 2020 | |||
| Epizyme Q1 2020 |
Epizyme Q2 2020 |
Epizyme Q3 2020 |
Epizyme Q4 2021 |
| May 4, 2020 | Aug. 4, 2020 | Nov. 6, 2020 | Feb. 23, 2021 |
| 2019 | |||
| Epizyme Q1 2019 |
Epizyme Q2 2019 |
Epizyme Q3 2019 press release |
Epizyme Q4 2019 |
| May 6, 2019 | August 9, 2019 | Oct. 30, 2019 | Feb. 24, 2020 |
2018 |
|||
| Epizyme Q4 2018 |
|||
May 8, 2018 |
Aug. 2, 2018 |
Nov. 2, 2018 |
Feb. 26, 2019 |
2017 |
|||
May 8, 2017 |
Aug. 4, 2017 |
Nov. 1, 2017 |
Mar. 13, 2018 |
2016 |
|||
05/09/2016 |
08/08/2016 |
11/03/2016 |
03/09/2017 |
2015 |
|||
Q2 na |
|||
Q1 |
08/06/2015 |
11/09/2015 |
03/09/2016 |
Older News:
Epizyme Should Pop When Tazemetostat Hold Clears by William Meyers [August 23, 2018 @ Seeking Alpha]
Epizyme Partnership with Celgene [July 13, 2015 @ Seeking Alpha]
Epizyme (EPZM) is a clinical-stage biotechnology pharmaceuticals comapny.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMGN |
| APRE |
| ARWR |
| BIIB |
| BMY |
| CLDX |
| EPZM |
| GILD |
| GLYC |
| ILMN |
| INCY |
| INO |
| IONS |
| MCHP |
| PLX |
| REGN |
| RNA |
| SAGE |
| SGEN |
| SYRS |
| TTPH |
| VBLT |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both my condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. This is investment journalism, not financial advice.
Copyright 2022 William P. Meyers